Wall Street Zen Downgrades Avalyn Pharma (NASDAQ:AVLN) to Sell

Avalyn Pharma (NASDAQ:AVLN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other equities research analysts have also recently weighed in on AVLN. Guggenheim began coverage on Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $80.00 price target for the company. Jefferies Financial Group assumed coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective on the stock. Weiss Ratings assumed coverage on Avalyn Pharma in a report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Morgan Stanley raised their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Finally, Evercore started coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Avalyn Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Stock Up 0.3%

NASDAQ:AVLN opened at $31.62 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The firm has a market capitalization of $1.40 billion and a price-to-earnings ratio of -1.39. Avalyn Pharma has a 12 month low of $24.15 and a 12 month high of $40.17. The company has a 50-day moving average price of $33.40.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.05. On average, research analysts expect that Avalyn Pharma will post -3.81 EPS for the current fiscal year.

Institutional Trading of Avalyn Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma in the 2nd quarter valued at $1,321,000. Braidwell LP acquired a new stake in shares of Avalyn Pharma during the second quarter worth $26,382,000. Finally, Montanova Capital LLC bought a new stake in Avalyn Pharma in the second quarter valued at about $82,402,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.